Literature DB >> 17024436

Asymmetric dimethylarginine is not elevated in exfoliation syndrome but symmetric dimethylarginine is related to exfoliative glaucoma.

Hillevi Blomster1, Tuomo Puustjärvi, Matti Kontkanen, Pirjo Valtonen, Markku Teräsvirta, Hannu Uusitalo.   

Abstract

BACKGROUND: Hyperhomocysteinemia (HH), oxidative stress and endothelial dysfunction are all implicated as possible pathogenetic factors in exfoliation syndrome (XFS) and exfoliative glaucoma (XFG). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide and plasma level of ADMA is often elevated in HH. Thus the present study was undertaken to study plasma levels of ADMA with concomitant measurement of symmetric dimethylarginine (SDMA) and L-arginine (L-Arg) in XFS and XFG.
METHODS: This cross-sectional, prospective study involved 36 XFS patients, 11 of them having XFG, and 36 age- and gender-matched controls. Fasting plasma ADMA, SDMA and L-Arg levels of participants were determined. A special view was created how plasma L-Arg, ADMA and SDMA correlate to plasma homocysteine (P-Hcy). In addition, the influence of P-Hey values derived from our previous study on the above mentioned parameters were evaluated by cut-off values of P-Hcy, 12 micromol/l for women and 14.5 micromol/l for men. RESULTS The mean plasma ADMA, SDMA and L-Arg levels were 0.41, 0.49 and 62.9 micromol/l in the XFS/XFG group, and 0.41, 0.44 and 69.7 micromol/l in the control group, respectively. As all parameters within the XFS and control group were compared, no statistical significance was stated. On the other hand, a positive correlation was observed between plasma SDMA and P-Hcy in XFGs (P = 0.002), and additionally, also a statistically significant difference was in plasma SDMA between the two groups sorted by cut-off levels of P-Hcy 0.49 +/- 0.15 vs. 0.36 +/- 0.04 micromol/l, above and below cut-off levels, respectively (P = 0.001), but not between ADMA in a respective assay. The mean values of L-Arg were 64.6 +/- 17.2 vs. 74.8 +/- 13.3 microg/l, respectively (P = 0.031). In the XFS subgroup, on the contrary, there was no positive correlation between P-Hcy and plasma SDMA.
CONCLUSIONS: A positive correlation of plasma SDMA in respect to P-Hcy in XFGs and increase of SDMA in mild or intermediate hyperhomocysteinemia may indicate SDMA as a marker of developing XFG in hyperhomocysteinemic

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17024436     DOI: 10.1007/s00417-006-0425-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  51 in total

1.  Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.

Authors:  V P Valkonen; H Päivä; J T Salonen; T A Lakka; T Lehtimäki; J Laakso; R Laaksonen
Journal:  Lancet       Date:  2001 Dec 22-29       Impact factor: 79.321

2.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease.

Authors:  M Cahill; M Karabatzaki; R Meleady; H Refsum; P Ueland; D Shields; D Mooney; I Graham
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 3.  Biological methylation of myelin basic protein: enzymology and biological significance.

Authors:  S Kim; I K Lim; G H Park; W K Paik
Journal:  Int J Biochem Cell Biol       Date:  1997-05       Impact factor: 5.085

4.  [Functional significance of adenosine receptors in the eye and their dysregulation in pseudoexfoliation syndrome].

Authors:  U Schlötzer-Schrehardt; M Zenkel; C Hofmann-Rummelt; F E Kruse; G O Naumann
Journal:  Ophthalmologe       Date:  2005-11       Impact factor: 1.059

5.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

Authors:  J T Kielstein; R H Böger; S M Bode-Böger; J Schäffer; M Barbey; K M Koch; J C Frölich
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

6.  8-Isoprostaglandin F2a and ascorbic acid concentration in the aqueous humour of patients with exfoliation syndrome.

Authors:  G G Koliakos; A G P Konstas; U Schlötzer-Schrehardt; G Hollo; I E Katsimbris; N Georgiadis; R Ritch
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

7.  Further evidence of interrelation between homocysteine and hypertension in stroke patients: a cross-sectional study.

Authors:  Eliyahu H Mizrahi; Shlomo Noy; Ben-Ami Sela; Yehudit Fleissig; Marina Arad; Abraham Adunsky
Journal:  Isr Med Assoc J       Date:  2003-11       Impact factor: 0.892

8.  Kynurenine and neopterin in the aqueous humor of the anterior chamber of the eye and in serum of cataract patients.

Authors:  Guna Laganovska; Agris Martinsons; Bronislavs Pitrans; Bernhard Widner; Dietmar Fuchs
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

9.  Association of neovascular age-related macular degeneration and hyperhomocysteinemia.

Authors:  Ruth Axer-Siegel; Dan Bourla; Rita Ehrlich; Gad Dotan; Yoav Benjamini; Slava Gavendo; Dov Weinberger; Ben-Ami Sela
Journal:  Am J Ophthalmol       Date:  2004-01       Impact factor: 5.258

10.  Hyperhomocystinemia in pseudoexfoliation glaucoma.

Authors:  Igal Leibovitch; Shimon Kurtz; Gabi Shemesh; Michaella Goldstein; Ben-ami Sela; Moshe Lazar; Anat Loewenstein
Journal:  J Glaucoma       Date:  2003-02       Impact factor: 2.503

View more
  3 in total

1.  Nailfold capillary morphology in exfoliation syndrome.

Authors:  C C Cousins; J H Kang; C Bovee; J Wang; S H Greenstein; A Turalba; L Q Shen; S Brauner; T Boumenna; S Blum; H Levkovitch-Verbin; R Ritch; J L Wiggs; P A Knepper; L R Pasquale
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

Review 2.  [Diagnosis and therapy of pseudoexfoliation glaucoma].

Authors:  A G M Jünemann
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

3.  Association Between the Asymmetric Dimethylarginine Levels and Glaucoma Severity: A Cross-Sectional Analysis of the LIGHT Study.

Authors:  Tadanobu Yoshikawa; Kenji Obayashi; Kimie Miyata; Keigo Saeki; Nahoko Ogata
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-04-01       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.